Royalty Pharma (RPRX) expects 2025 Portfolio Receipts to be between $3,200 million and $3,250 million, previously $3,050 million to $3,150 million, representing expected growth of 14% to 16%.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma acquires royalty interest in Alnylam’s AMVUTTRA for $310M
- Royalty Pharma price target lowered to $54 from $55 at Morgan Stanley
- Royalty Pharma: Strategic Positioning and Growth Potential Drive Buy Rating
- Royalty Pharma initiated with a Buy at Goldman Sachs
- Royalty Pharma appoints Ted Love as lead independent director